[PDF] Top 20 PARP inhibitor combination therapy.
Has 10000 "PARP inhibitor combination therapy." found on our website. Below are the top 20 most common "PARP inhibitor combination therapy.".
PARP inhibitor combination therapy.
... Combinations of vascular endothelial growth factor receptor inhibitors (VEGFRi) with several chemotherapies have already been licensed for treatment in metastatic colorectal cancer, renal cancer, and advanced non- ... See full document
42
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
... multimodal therapy, including strategies from traditional chemotherapeutic agents, radiotherapy, and surgery, the current cure rate of ES patients with localized disease is 70% [2, ...6]. PARP proteins play ... See full document
16
Validation of HPLC Method for Simultaneous Determination of Galantamine Hydrobromide/Pymadine
... multi-target therapy of Alzheimer’s disease by the combination of acetylcholinesterase inhibitor with a potential synergist, and due to the fact that in literature and pharmacopoeial articles, the ... See full document
15
HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy
... micelle-based nanoporphyrin platform, for the integration a broad range of imaging and therapeutic functions that include near infra-red fluorescence imaging (NIRFI), positron emission tomography (PET), magnetic ... See full document
12
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
... and combination groups for IB115 and n = 5 for vehicle and rucaparib groups and n = 8 for trabectedin and combination groups in PDX) 2 weeks after the tumor became meas- urable (15 days after injection: day ... See full document
10
Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review
... a combination of terms: adult-onset Still’s disease, AOSD, bio- logical therapy, biologics, TNF- α inhibitor, IL-1 inhibitor, IL-6 inhibitor, IL-18 inhibitor, infliximab, ... See full document
5
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
... damaging therapy in ...clinically-used PARP inhibitor [8] for combination chemotherapy but subsequent studies identified the synthetic lethality of PARP inhibitor monotherapy in ... See full document
14
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
... The current study presents durable long-term activity and safety outcome of the 3-pathway modulation with a median of 8 months follow-up (range 1 to 26+ months) and a RR worthy of further investigation. Single agent ... See full document
8
A decade of clinical development of PARP inhibitors in perspective.
... (PARP) inhibitor olaparib clinically validated the synthetic lethal interaction between inhibition of PARP1, a key sensor of DNA damage, and BRCA1/ BRCA2 ...of PARP inhibitor clinical ... See full document
11
Induction maintenance with tumour necrosis factor inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta analysis of efficacy in randomised controlled trials
... initial combination therapy (MTX +TNFi) was compared with MTX monotherapy in adult patients with clinically active early RA, de fi ned as disease duration <1 year or symptom duration <2 years; (2) dis- ... See full document
10
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
... cause PARP-trapping where PARP enzyme does not disengage from the damaged DNA sites which not only leads to unrepaired SSBs but also to generation and persistence of secondary ...trapped PARP-DNA ... See full document
11
Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
... The combination of an incretin-based therapy and insulin is a promising approach to optimize the management of glycemic control without hypoglycemia and weight ...peptidase-4 inhibitor, has a unique ... See full document
14
Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo
... of PARP-1, as well as the extent of PARP-1 inhibition, in tumors in order to eliminate patients that are unlikely to respond to PARP-1 inhibitor ...and combination therapy is ... See full document
42
Bicalutamide and Third-Generation Aromatase Inhibitors in Testotoxicosis
... of combination therapy with a potent antiandrogen agent (bicalutamide) and a third-generation aromatase inhibitor (anastrozole or letrozole) was reported to yield encouraging short-term ...this ... See full document
8
Biological Modulation of Parp Inhibition in Triple Negative Breast Cancer, a Combinational Approach Implementing Multitargeted Epigenetic Therapy (Mtet) with Parp Inhibition, in Advanced Breast Cancer: A Case Study
... Cancer Therapy enzyme is trapped at certain DNA damage ...on combination of epigenetic therapies with PARP inhibitors [5] ...the combination of epigenetic therapies consisting of the protocol ... See full document
11
<p>First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers</p>
... of PARP-1 activation has been reported as a potential ther- apeutic option for providing neuroprotection by diminish- ing the infarct size, shrinking edema volume, and attenuating neurovascular unit damage after ... See full document
11
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma
... in B cell lymphomas by proteasome inhibitors is mediated by p53 (45–48). Similarly, a possible explanation for the Btz-induced apoptosis seen in our PEL model was posttranslational stabiliza- tion of phosphorylated and ... See full document
14
Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
... on combination nivolumab and ipilumimab therapy who developed concurrent hypophysitis, type 1 diabetes mellitus (T1DM) and diabetes ...of combination treatment with a headache, myalgias and ... See full document
5
Original Article Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells
... for certain tumors with suppressor gene muta- tions, such as BRCA mutation breast cancer, which will greatly increase the treatment effects [6, 12]. The increase of DNA damage, cell apop- tosis and radiosensitivity of ... See full document
6
Advances and perspectives of PARP inhibitors
... PARPi therapy has a substantial influence on systemic immune response ...SCLC, combination therapy of Olaparib and anti-PD- L1 showed more potent anti-cancer effect than mono- therapy and ... See full document
12
Related subjects